AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) investors are busy throwing a party today following the news that tiny drug maker has sold its U.
Maxim’s Jason Kolbert bets AEZS’ oral test could set a new standard in addressing Adult Growth Hormone Deficiency (AGHD) with FDA approval now under its belt.
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold or wins the regulator’s bless. …
December is an exciting month for AEterna Zentaris Inc. (NASDAQ:AEZS) investors, with the upcoming PDUFA on December 30 for Macrilen (macimorelin), for the evaluation …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the Marketing Authorization Application (MAA) for the use of Macrilen™ (macimorelin) for the evaluation of adult …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the third quarter ended September 30, 2017.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it has received notice from the NASDAQ Listing Qualifications Department (“NASDAQ”) determining that the Company is eligible …
Aeterna Zentaris Inc. (USA) (NASDAQ:AEZS) and EMD Serono, Inc.
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), with a $2.
